12/18
10:09 am
rgls
Polycystic Kidney Diseases Therapeutics Market Report 2024: Comprehensive Insights About 8+ Companies and 10+ Pipeline Drugs [Yahoo! Finance]
Medium
Report
Polycystic Kidney Diseases Therapeutics Market Report 2024: Comprehensive Insights About 8+ Companies and 10+ Pipeline Drugs [Yahoo! Finance]
11/26
08:06 am
rgls
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences [Yahoo! Finance]
Medium
Report
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences [Yahoo! Finance]
11/26
08:00 am
rgls
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Low
Report
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
11/11
08:09 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/7
04:05 pm
rgls
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Neutral
Report
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
10/30
09:25 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/29
06:04 am
rgls
These 2 ‘Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts [Yahoo! Finance]
Medium
Report
These 2 ‘Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts [Yahoo! Finance]
10/8
03:48 pm
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/8
08:00 am
rgls
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
High
Report
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)